8-K: Inhibrx Biosciences Shareholders Elect Directors and Ratify Auditor at 2025 Annual Meeting

Inhibrx Biosciences, Inc. announced the successful completion of its 2025 Annual Meeting of Stockholders, where key governance matters including director elections and auditor ratification were approved.

Summary

• The 2025 Annual Meeting of Stockholders for Inhibrx Biosciences, Inc. was held virtually on May 28, 2025, at 10:00 a.m. Pacific Time.
• A quorum of 11,493,284 shares, representing approximately 79% of the 14,475,904 eligible shares outstanding as of the April 1, 2025 record date, was present or represented by proxy.
• Shareholders elected Jon Faiz Kayyem, Ph.D. and Kristiina Vuori, M.D., Ph.D. as Class I Directors, each to serve until the 2028 Annual Meeting.
• Jon Faiz Kayyem, Ph.D. received 8,077,611 votes For and 31,060 votes Withheld.
• Kristiina Vuori, M.D., Ph.D. received 6,494,317 votes For and 1,614,354 votes Withheld.
• The selection of BDO USA, P.C. as the company's independent registered public accounting firm for the year ending December 31, 2025, was ratified by shareholders with 11,463,328 votes For, 2,918 votes Against, and 27,038 votes Abstained.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of the annual shareholder meeting with all proposals approved, indicating stable corporate governance and routine operations without any negative surprises.

Positives

• All proposed resolutions, including the election of directors and the ratification of the independent auditor, were approved by shareholders.
• A strong quorum of approximately 79% of eligible shares indicates active shareholder participation and engagement in corporate governance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

This 8-K filing is a routine corporate governance update, reporting the outcomes of the annual shareholder meeting. It reflects standard compliance with SEC regulations for publicly traded companies and does not provide information directly related to broader industry trends or competitive landscape beyond general corporate operations.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The election of directors and ratification of the auditor provide stability and continuity in corporate governance, which is generally positive for shareholder confidence.
• Management: The confirmed board composition allows management to continue executing the company's strategy with clear oversight.
• Regulatory Authorities: The filing demonstrates compliance with SEC reporting requirements for annual meeting results.

Next Steps

• The newly elected Class I Directors, Jon Faiz Kayyem, Ph.D. and Kristiina Vuori, M.D., Ph.D., will serve until the 2028 Annual Meeting.
• BDO USA, P.C. will serve as the independent registered public accounting firm for the year ending December 31, 2025.

Key Dates

Recommendation

Keywords

Inhibrx Biosciences, INBX, Annual Meeting, Stockholders, Director Election, Auditor Ratification, Corporate Governance, SEC Filing, 8-K